These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36594243)

  • 41. When dysbiosis meets dystrophy: an unwanted gut-muscle connection.
    Jayaraman A; Pettersson S
    EMBO Mol Med; 2023 Mar; 15(3):e17324. PubMed ID: 36843560
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Perturbation of PI3K/Akt signaling affected autophagy modulation in dystrophin-deficient myoblasts.
    Yazid MD; Hung-Chih C
    Cell Commun Signal; 2021 Oct; 19(1):105. PubMed ID: 34706731
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mitochondrial content is preserved throughout disease progression in the mdx mouse model of Duchenne muscular dystrophy, regardless of taurine supplementation.
    Barker RG; Wyckelsma VL; Xu H; Murphy RM
    Am J Physiol Cell Physiol; 2018 Apr; 314(4):C483-C491. PubMed ID: 29351413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.
    Gehrig SM; van der Poel C; Hoeflich A; Naim T; Lynch GS; Metzger F
    Growth Horm IGF Res; 2012 Apr; 22(2):69-75. PubMed ID: 22424862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy.
    Amor F; Vu Hong A; Corre G; Sanson M; Suel L; Blaie S; Servais L; Voit T; Richard I; Israeli D
    J Cachexia Sarcopenia Muscle; 2021 Jun; 12(3):677-693. PubMed ID: 34037326
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neopterin/7,8-dihydroneopterin is elevated in Duchenne muscular dystrophy patients and protects mdx skeletal muscle function.
    Lindsay A; Schmiechen A; Chamberlain CM; Ervasti JM; Lowe DA
    Exp Physiol; 2018 Jul; 103(7):995-1009. PubMed ID: 29791760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy.
    Kourakis S; Timpani CA; de Haan JB; Gueven N; Fischer D; Rybalka E
    Redox Biol; 2021 Jan; 38():101803. PubMed ID: 33246292
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
    St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
    Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy.
    Abou-Samra M; Selvais CM; Boursereau R; Lecompte S; Noel L; Brichard SM
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):518-533. PubMed ID: 31965757
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Autophagy as a new therapeutic target in Duchenne muscular dystrophy.
    De Palma C; Morisi F; Cheli S; Pambianco S; Cappello V; Vezzoli M; Rovere-Querini P; Moggio M; Ripolone M; Francolini M; Sandri M; Clementi E
    Cell Death Dis; 2012 Nov; 3(11):e418. PubMed ID: 23152054
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Growth Hormone Increases Bone Toughness and Decreases Muscle Inflammation in Glucocorticoid-Treated Mdx Mice, Model of Duchenne Muscular Dystrophy.
    Yoon SH; Grynpas MD; Mitchell J
    J Bone Miner Res; 2019 Aug; 34(8):1473-1486. PubMed ID: 31188496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Delayed bone regeneration is linked to chronic inflammation in murine muscular dystrophy.
    Abou-Khalil R; Yang F; Mortreux M; Lieu S; Yu YY; Wurmser M; Pereira C; Relaix F; Miclau T; Marcucio RS; Colnot C
    J Bone Miner Res; 2014 Feb; 29(2):304-15. PubMed ID: 23857747
    [TBL] [Abstract][Full Text] [Related]  

  • 53. IP
    Valladares D; Utreras-Mendoza Y; Campos C; Morales C; Diaz-Vegas A; Contreras-Ferrat A; Westermeier F; Jaimovich E; Marchi S; Pinton P; Lavandero S
    Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3685-3695. PubMed ID: 30251688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The D2.mdx mouse as a preclinical model of the skeletal muscle pathology associated with Duchenne muscular dystrophy.
    Hammers DW; Hart CC; Matheny MK; Wright LA; Armellini M; Barton ER; Sweeney HL
    Sci Rep; 2020 Aug; 10(1):14070. PubMed ID: 32826942
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
    Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
    J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paeonia lactiflora extract improves the muscle function of mdx mice, an animal model of Duchenne muscular dystrophy, via downregulating the high mobility group box 1 protein.
    Sim I; Jang J; Song J; Lee J; Lim H; Lee HJ; Hwang G; Kwon YV; Lee D; Yoon Y
    J Ethnopharmacol; 2022 May; 289():115079. PubMed ID: 35149132
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy.
    Chesshyre M; Ridout D; Hashimoto Y; Ookubo Y; Torelli S; Maresh K; Ricotti V; Abbott L; Gupta VA; Main M; Ferrari G; Kowala A; Lin YY; Tedesco FS; Scoto M; Baranello G; Manzur A; Aoki Y; Muntoni F
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1360-1372. PubMed ID: 35083887
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mineralocorticoid receptor antagonists and glucocorticoids differentially affect skeletal muscle inflammation and pathology in muscular dystrophy.
    Howard ZM; Gomatam CK; Rabolli CP; Lowe J; Piepho AB; Bansal SS; Accornero F; Rafael-Fortney JA
    JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
    Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
    Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Muscle ERRγ mitigates Duchenne muscular dystrophy via metabolic and angiogenic reprogramming.
    Matsakas A; Yadav V; Lorca S; Narkar V
    FASEB J; 2013 Oct; 27(10):4004-16. PubMed ID: 23781095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.